Hepatocyte Growth Factor (HGF) exerts its biological eects via binding and activating a transmembrane protein tyrosine kinase receptor known as c-Met. Previous studies from our laboratory demonstrated that c-met gene expression is inducible by its own ligand (HGF). However, the molecular mechanism(s) involved in this process are unknown. The present study was carried out to address this question. Transfection of various c-met-CAT promoter constructs into the mouse hepatocellular carcinoma cell line Hepa 1-6 in combination with electrophoretic mobility shift assays (EMSA) identi®ed the responsive element as an activated protein-1 (AP-1) binding site (TGAGTCA) within the c-met core promoter region at position 7158 to 7152. The c-met AP-1 element binds speci®cally to AP-1 protein as veri®ed by supershift assays. EMSA studies and mutational analyses of the promoter region also revealed that the members of the Sp family of transcription factors (Sp-1 and Sp-3) bind to the c-met Sp-1 element (located at position 7124) which is adjacent to the AP-1 site. We show that Sp binding dampens binding of AP-1 to its cognate site in the c-met promoter region. Stimulation of Hepa 1-6 cells with HGF resulted in a rapid and dramatic enhancement of the AP-1 binding activity as well as an overall increase in the level of AP-1 protein. Cotransfection of AP-1 expression vectors (c-Fos plus c-Jun) with cmet promoter constructs resulted in stimulation of c-met promoter activity. We found that transactivation of the cmet promoter by AP-1 can be blocked by Curcumin, an inhibitor of AP-1. Moreover, we found that the induction of the endogenous c-met gene by HGF is inhibited by the addition of Curcumin. The results demonstrate that the HGF-induced transcription of the c-met gene by HGF is, at least in part, due to activation of the AP-1 pathway.
Introduction
The c-met proto-oncogene encodes a transmembrane glycoprotein cell surface receptor with tyrosine kinase activity, and its ligand is called hepatocyte growth factor (HGF) (Bottaro et al., 1991; Naldini et al., 1991) . Upon binding to HGF, c-Met activates multiple intracellular signaling pathways and transduces the mitogenic, motogenic and morphogenic signals of HGF, regulating cell growth and dierentiation in various cell types (Jeers et al., 1996; Tamagnone and Comoglio, 1997; Zarnegar and Michalopoulos, 1995) . In vivo experiments using transgenic mice demonstrated that HGF/c-Met signaling plays a critical role in embryogenesis, organ development and tissue regeneration (Bladt et al., 1995; Uehara et al., 1995) . Moreover, aberrant expression of the c-met and/or HGF gene in transgenic mice has been shown to contribute to oncogenic transformation and tumor progression (Bell et al., 1999; Jeers et al., 1998) .
Although substantial eort has been devoted toward understanding the functions of HGF/c-Met, the molecular mechanisms that control the transcription of the cmet gene are still unclear. Previously, we and others reported that c-met expression is inducible by cytokines including the c-Met ligand HGF (Boccaccio et al., 1994; Chen et al., 1997) ; however, the mechanisms involved were not investigated. In our previous papers, we have described the cloning and characterization of the mouse c-met gene promoter region and showed the involvement of Sp-1 and p53 proteins in the regulation of c-met promoter activity (Seol and Zarnegar, 1998; Seol et al., 1999) . Ets1 transcription factor has also been reported to upregulate the transcription of the c-met gene (Gambarotta et al., 1996) . We showed that the 200 bp promoter fragment which contains the basal promoter is sucient to confer responsiveness to HGF in transient transfection assays . Therefore, the current study was designed to identify and characterize the HGF responsive element(s) in the c-met gene promoter.
Results and discussion
The c-met gene 5'-flanking region confers inducibility in response to HGF We previously demonstrated that the expression of the c-met gene is inducible by HGF and that the 200 bp region from 7278 to 776 (relative to the transcription start site) of the core promoter is not only required for maximal promoter function but also possesses an element(s) responding to cytokine stimulation Seol and Zarnegar, 1998) . To extend these studies, we generated additional 5'-deleted mouse c-met-CAT reporter constructs and analysed them to de®ne the HGF responsive element(s) using transient transfection into Hepa 1-6 cells followed by CAT assays. We found that promoter activity of the 7278 c-met-CAT construct was upregulated by HGF treatment by approximately ®vefold as expected. The 7209 c-met-CAT construct was also responsive to HGF; however, the 7120 met-CAT construct was unresponsive to the stimuli. Moreover, the basal activity of the 7120 c-met-CAT promoter was dramatically reduced as compared to the other two constructs (data not shown). These results indicated that the promoter region from 7209 to 7120 contains cis-acting element(s) which are important for mediating inducible c-met gene expression in response to HGF.
Characterization of the nuclear factors binding to the c-met gene promoter region: AP-1 and Sp family of proteins interact with the c-met gene promoter through their binding sites
To study the mechanisms of the transcriptional regulation of the c-met gene, the promoter region was characterized by computer-assisted sequence analysis followed by functional assays. Computer analysis of the region from 7209 to 777 only identi®ed a perfect AP-1 binding site at position 7158 in addition to a perfect Sp-1 site at position 7124 ( Figure 1a ). This is a noteworthy ®nding since the AP-1 family of transcription factors is known to mediate gene induction in response to growth factors (Ahmad et al., 1998; Lee et al., 1987; MarksKonczalik et al., 1998; Zhang et al., 1998) . To identify factors that bind to the c-met promoter and mediate responsiveness to HGF, the promoter fragment (7170 to 777) designated P1 ( Figure 1a ) was labeled and used as a probe in electrophoretic mobility shift assays (EMSA) utilizing Hepa 1-6 cell nuclear protein extracts. Overlapping oligonucleotides covering the promoter region ( Figure 1a ) were synthesized and used as competitors/probes in these assays. As depicted in Figure 1b , P1 probe formed ®ve speci®c complexes which we have named C1 to C5, respectively. A 50-fold molar excess of the unlabeled P1 oligomer eectively competed with the labeled P1 probe for all of the complexes formed (C1 ± C5) ( Figure 1b, lanes 3 and 4) . Excess amount of unlabeled oligomer F1, which covers the region from 7170 to 7146 and contains a putative AP-1 binding site, completely abolished the formation of complexes C1 and C4 (lanes 5 and 6). On the other hand, F4 region which contains an Sp-1 binding site abrogated the formation of complexes C2, C3 and C5 (lanes 11 and 12). F2, F3 and F5 oligonucleotides, however, did not aect (compete) the binding of any of the complexes (lanes 7 ± 10, and lanes 13 and 14).
Since formation of the major complexes (C2 and C3) was prevented by the F4 competitor (7130 to 7111) which contains one Sp-1 site, we tested whether these complexes resulted from the binding of Sp family member proteins (i.e. Sp-1 and/or Sp-3). We found that the C1, C2, C3 and C5 complexes bound to the P1 probe were competed fully by F4 as well as by the consensus Sp-1 binding element ( Figure 2a ). The mutant F4 (mtF4) oligonucleotide, which has two mutated nucleotides in the core Sp-1 binding element, lost the ability to compete (Figure 2a ). Supershift assays using anti-Sp-1 and Sp-3 antibodies and the F4 fragment as a probe revealed that C2, C3 and C5 indeed contain Sp-1 and Sp-3 proteins ( Figure 2b ). Complex C4 was only competed by F1 oligonucleotide (Figure 2a ).
EMSA was then performed to identify the proteins binding to the F1 region (7170 to 7146). Double stranded F1 oligonucleotide was radiolabeled and used as a probe in EMSA. As shown in Figure 3 , F1 formed one major speci®c shifted band because the formation of this complex was competed by unlabeled oligonucleotide F1 as well as by a commercially available oligonucleotide containing consensus AP-1 binding site but not by mutant F1 (mtF1) oligonucleotide. Unrelated oligos such as Sp-1 and Myc binding sites did not compete ( Figure 3) . Moreover, the formation of the shifted complex was blocked by an anti-AP-1 antibody (anti c-Jun antibody, Figure 3 ). These results indicated that Ap-1 protein speci®cally interacts with the c-met gene promoter through the AP-1 binding site located in the F1 region (position 7170 to 7146). (7170 to 777). F1 ± F5 are overlapping oligonucleotides corresponding to various regions of the promoter as indicated. These fragments which cover the region from 7170 to 777 were used in electrophoretic mobility shift assays (EMSA) as competitors as indicated in the ®gure. (b) Representative EMSA in which P1 was end-labeled with g-32 P-dATP by T4 kinase and used as a probe with nuclear extract from Hepa 1-6 cells. C1 ± C5 indicate the speci®c complexes (bands) shifted by nuclear factors. As indicated, 50-or 100-fold molar excess of dierent oligonucleotides was used as a competitor Binding of Sp proteins to the c-met promoter reduces AP-1 binding to the c-met promoter As we mentioned above, complex C1 was competed by the AP-1 site. The C1 band also disappeared when F4/ Sp-1 binding site was used as a competitor (see Figure  1b , lanes 11 and 12; and Figure 2a ). To de®ne the relationship of AP-1 and Sp-1 in their binding to the cmet promoter, EMSA was carried out using the P1 (7170 to 777) fragment as a probe. As shown in Figure 4a , the C1 complex as well as C2, C3 and C5 were competed by an excess amount of oligonucleotide corresponding to the c-met Sp-1 binding site (F4). On the other hand, the C4 complex was not abrogated and, in fact, became stronger. Antibody against (c-Jun) aected (inhibited and partially shifted) the C4 complex, but control antibody (anti-C/EBP antibody) did not. These results indicated that Sp1 binding could potentially interfere with AP-1 binding. To test this possibility, the Sp-1 binding site in the P1 probe was mutated and then used as a probe (the mutations are the same as indicated in mutant F4 in Figure 2 ). The mutated P1 probe only formed an AP-1 containing complex (C4), which was competed for by the F1 fragment and supershifted/inhibited by anti-AP-1 antibody (Figure 4b ). These results suggested that the C1 complex resulted from the binding of both AP-1 and Sp proteins (Sp-1 plus Sp-3) to the P1 region and that Sp binding dampened AP-1 binding.
Sp-1 protein is known as a ubiquitously and constitutively expressed transcription factor (Janson and Pettersson, 1991; Kida et al., 1999; Leiden et al., 1989) . Although Sp-1 by itself has the ability to activate the transcription of target genes, several lines of evidence indicate that Sp-1 also interacts and functionally cooperates with other transcription factors (Srivastava et al., 1998) . Our binding experiments demonstrated that Sp proteins (Sp-1 plus Sp-3) interact with the c-met promoter and reduce AP-1 binding to the c-met promoter. This inhibition may be caused by steric hindrance rather than by direct competition, since the binding sites of AP-1 and Sp-1 are separated by approximately 30 bp. Sp proteins may dominate because of their higher amount/anity than AP-1, since we found that Sp-3 also binds to the Sp-1 site and since it is reported that Sp-3 may regulate gene expression in a positive as well as negative manner (Jiang et al., 1997) . It is possible that Ap-1 binding dampens the negative eects of Sp-3 and further induces c-met gene expression.
Enhanced c-met promoter activity by forced overexpression of AP-1 protein
To study the potential role of AP-1 in the regulation of cmet promoter activity, dierent c-met promoter constructs (7278met-CAT, 7209met-CAT, and 7120met-CAT) were cotransfected with c-Jun and c-Fos expression Figure 2 Sp-1 and Sp-3 bind to the c-met core promoter. (a) EMSA was performed using P1 as a probe. Oligonucleotides corresponding to the c-met Sp-1 binding site (F4) and the published high anity Sp-1 binding site competed eectively for C1, C2, C3 and C5 formation but not for C4, which could be competed by F1. On the other hand, the mutant form of F4 (mt F4) did not compete for any bands. (b) Supershift assay was carried out using anti Sp-1 and Sp-3 antibodies. An oligonucleotide corresponding to the c-met Sp-1 binding site (F4) was labeled and used as a probe; the shifted complexes (C2, C3 and C5) were supershifted by anti-Sp-1 and Sp-3 antibodies. The sequences for F4, mutant F4 and the published Sp-1 site are shown in the ®gure with the core binding site indicated by bold face plasmids. In addition, a mutant Sp-1 site construct (7278met-CATmtSp-1) was made in which the Sp-1 binding site at position 7124 (see Figure 2 ,`mtF4') in the 7278met-CAT was mutated by site directed mutagenesis. The results revealed that overexpression of AP-1 protein (c-Jun plus c-Fos) signi®cantly (by approximately ®vefold) enhanced the c-met promoter activity of the 7278met-CAT and the 7209met-CAT constructs but not the 7120metCAT construct as compared to vector transfected controls (data not shown). Mutation of the Sp-1 site at position 7124 did not diminish the transactivation eect of AP-1 on the c-met promoter (data not shown) although it did result in an overall reduction in the basal transcription activity of the c-met promoter. Moreover, addition of Curcumin, which is a known inhibitor of AP-1 activity (Ahmad et al., 1998; Chen and Tan, 1998; Huang et al., 1991) , abolished the transactivation function of AP-1 (c-Jun plus c-Fos) on the c-met promoter in a dose dependent manner (reaching a maximum of eect at 10 mM, data not shown). Mithramycin, which is known to interfere with Sp-1-mediated gene expression and protein binding function (Blume et al., 1991; Greenwel et al., 1997) , did not in¯uence AP-1-mediated induction of the c-met promoter (data not shown).
HGF stimulates AP-1 binding to the c-met gene promoter
It is known that AP-1 is rapidly activated after stimulation by cytokines and other agents (Ahmad et al., 1998; Lee et al., 1987; Marks-Konczalik et al., 1998; Zhang et al., 1998) . The phosphorylated AP-1 complex binds to its cognitive binding site (TGAGT-CA) and regulates gene expression (Karin, 1995) . To study if AP-1 is activated by HGF, the following experiments were performed. Hepa 1-6 cells were grown in serum-free medium for 24 h and then treated with HGF for 1 h and 3 h, respectively. Nuclear protein was extracted, and EMSA and Western blot analysis were performed. When F1 fragment (which has a perfect AP-1 binding site) was used as a probe in EMSA, a dramatic enhancement of AP-1 binding to the c-met AP-1 site was noted after cells were treated with HGF for 1 h ( Figure 5 ). Western blot analysis using anti-c-Jun antibody indicated that the level of AP-1 protein in HGF-treated nuclear extracts was only modestly increased by approximately 50% as compared to the untreated control extract (data not shown). Thus, the dramatic increase in AP-1 binding activity could be the result of post-translational modi®cation of c-Jun protein and/or expression of other members of the AP-1 family. It is known that HGF, by binding to its membrane receptor c-Met, activates Ras and subsequently the MAPK pathway which in turn activates AP-1 (Mae and Comoglio, 1998; Rodrigues et al., 1997) . In support of the present data, we have previously reported that HGF stimulates the mRNA expression of the AP-1 family (c-jun and c-fos) in cultured hepatocytes (Weir et al., 1994) . Boccoccio et al. (1994) have also reported that HGF increases the level of c-jun and c-fos mRNA within 30 min in carcinoma cell lines. 
HGF induced c-met gene expression is inhibited by Curcumin
To study the eect of AP-1 and HGF on endogenous c-met gene expression, Hepa 1-6 cells were plated and treated with or without Curcumin for 1 h, and then HGF was added to the cells for another hour. Total RNA was isolated from each sample and Northern blot analysis was performed to detect c-met mRNA expression. HGF induced c-met mRNA expression and the induction was abrogated by the addition of Curcumin in a dose dependent manner reaching a maximum eect at 10 mM (data not shown). Inhibition of HGF-induced c-Met expression by Curcumin was also seen at the protein level as determined by Western blot analysis for c-Met protein (data not shown). Taken together, our results show that HGF transcriptionally regulates the gene expression of its own receptor, at least in part, through activation of AP-1.
Materials and methods

Cell culture and reagents
Mouse and human hepatocellular carcinoma cell lines Hepa 1-6 and Hep-G2 were purchased from American Type Culture Collection (Rockville, MD, USA). Cells were maintained in DMEM supplemented with 10% bovine calf serum, penicillin (100 mg/ml) and streptomycin (100 mg/ml) at 378C and 5% CO 2 in air. Before treatment, cells were washed and incubated overnight in serum-free DMEM. Recombinant human HGF (R&D Systems, Inc., Minneapolis, MN, USA) or Curcumin (Sigma) was then added to cells in the concentration indicated in the text. The antibodies for supershift assays included C/EBP (sc-1506), Sp-1 (sc-596), and (sc-456) and were purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA.
Oligonucleotides and DNA vectors
The P1 and F5 DNA fragments were obtained by polymerase chain reaction (PCR) using the 1.6mc-met-CAT construct as the template (Seol and Zarnegar, 1998) . The primer sequences used in PCR are: P1 forward: 5'-CTGTTGCCCGGCTG-AGTCAC, P1 reverse: 5'-CTGCGGCCCGGGCCGA AC-CC, and F5 forward: GGAGCAGTCCGAGGGCGCTC. The F5 reverse is the same as the P1 reverse primer. The high anity binding sites for AP-1, Sp-1 and Myc were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Other oligonucleotides used in the paper were chemically synthesized in the Department of Biological Science at the University of Pittsburgh, USA. The actual sequences of all the oligonucleotides are listed in the respective ®gures. The cmet gene promoter constructs were made as described previously (Seol and Zarnegar, 1998) . Brie¯y, to obtain the 7278 mc-met-CAT construct, the HindIII ± ApaI fragment of the mouse c-met promoter (7278 to +184 relative to the transcription start site) was cloned into the promoterless pCAT-Basic plasmid (Promega, WI, USA). The 7278 mcmet-CAT/Sp-1 mutant construct was prepared by sitedirected mutagenesis of the Sp-1 binding site (7124) of the 7278 mc-met-CAT construct. The oligonucleotide-directed mutagenesis was conducted using the Transformer sitedirected mutagenesis kit (Clontech, CA, USA) according to the manufacturer's instructions. The 7209 mc-met-CAT vector (7209 to +183) was obtained by digestion of the 1.6 mc-met-CAT construct with ApaI and KpnI, followed by self-ligation. To generate the 7120 mc-met-CAT construct (7120 to +184), the corresponding DNA fragment obtained by PCR was cloned into the pCAT-Basic plasmid. The Jun and Fos expression plasmids pCMV-Jun and pCMV-Fos were the generous gifts of Thomas Curran (Sonnenberg et al., 1989) .
Preparation of nuclear extracts
Nuclear protein extracts were prepared from control and HGF treated Hepa 1-6 cells. Hepa 1-6 cells were plated in 150-mm petri dishes and maintained in serum-free DMEM for 24 h. Cells were or were not treated with HGF as indicated in the ®gure legends, and nuclear protein was isolated as described previously (Liu et al., 1994) . The protein concentration was measured by the BSA assay (BioRad).
Electrophoretic mobility shift assay (EMSA)
Binding reactions were combined with 1 mg of sample protein in 10 ml of binding buer (2 mM HEPES, pH 7.9, 10 mM KCl, 0.2 mM EDTA, 12% (v/v) glycerol, 0.5 mM DTT, 0.5 mM PMSF and 1 mg of poly(dI-dC)). About 10 000 c.p.m. of g 32 P-labeled oligonucleotide was added to each reaction, and the reactions were carried out at room temperature for 10 min. In the competition and supershift experiments, competitors and antibodies were ®rst incubated with the nuclear protein for 10 min at room temperature and the radioactive probe was then added in each reaction and incubated for additional 10 min. DNA-protein complexes were electrophoresed on native 5% polyacrylamide gels in 0.56TBE buer. Following electrophoresis, the gels were dried and subjected to autoradiography at 7708C.
Transfection and chloramphenical acetyltransferase (CAT) assay
The LipofectAMINE mediated DNA delivery method (Life Technologies, MD, USA) was used in transfection assays. In transient transfection experiments, Hepa 1-6 cells were transfected with various CAT constructs plus a b-galactosidase plasmid, pCMV-b-Gal. The latter was used as an internal control for transfection eciency. Cells were harvested 48 h after transfection. CAT assays were carried Figure 5 HGF enhances the binding of AP-1 to the c-met AP-1 element. EMSA was performed using HGF-treated and control untreated Hepa 1-6 cell nuclear protein extracts and the c-met AP-1 site (F1) as a probe. Dierent competitors and anti-AP-1 antibody were used to test the speci®c binding of AP-1 out using cell lysates according to the standard protocol (Liu et al., 1994) . CAT activity was normalized by the bgalactosidase activity in cell lysates.
Western blot analysis
Equal amounts of protein extract were electrophoresed on sodium dodecyl sulfate (SDS) ± polyacrylamide gel, and proteins were transferred to PVDF membrane (Amersham Corporation, IL, USA). Ponceau S staining was performed to ensure equal loading and proper transferring. The membranes were probed with rabbit anti-c-Jun and anti-c-Met antibody (Santa Cruz Biotechnology, Inc., CA, USA), respectively, followed by horseradish-conjugated goat antirabbit IgG (Sigma) . The signal was visualized by the enhanced chemiluminescent system (NEN life science products, Boston, MA, USA) according to the manufacturer's recommendations.
